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Abstract
Purpose: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare group of tumors with a wide spectrum of
clinical behavior. However, there are no known clinically relevant biomarkers to predict metastasis.
Experimental Design: To investigate differential gene expression signatures of metastatic vs non-metastatic NETs, we
studied cell cycle regulatory genes in 19 metastatic and 22 non-metastatic colorectal NETs by PCR arrays.
Immunohistochemistry (IHC) and quantitative real-time RT-PCR were performed to verify the results and another set of
38 GEP-NETs were further studied for validation.
Results: We first delineated six candidate genes for metastasis including ATM, CCND2, RBL2, CDKN3, CCNB1, and GTSE1. ATM
was negatively correlated with metastatic NETs (p,0.001) with more than 2-fold change compared to non-metastatic NETs.
Overexpression of ATM protein by IHC was strongly correlated with high ATM mRNA levels and low Ki-67 labeling index.
Patients with ATM-negativity by IHC showed significantly decreased overall survival than patients with ATM-positivity
(median OS, metastatic vs non-metastatic NETs; 2.7 years vs not reached; p=0.003) and 85.7% of metastatic NETs were ATM-
negative. In another validation set of GEP-NETs, decreased mRNA of ATM gene was associated with metastasis and remained
significant (p=0.023).
Conclusions: ATM down-regulation was strongly associated with metastatic NETs when compared with non-metastatic
NETs and ATM may be a potential predictive marker for metastasis as well as a novel target in metastatic GEP-NETs.
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Introduction
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
are a heterogeneous group of malignancies derived from
neuroendocrine cell compartments in various organs including
pancreas, colorectum, biliary tract, and stomach. Data from recent
population-based studies demonstrate a significant increase in the
reported incidence of NETs over time and the incidence ranges
from 2.5 to 5 cases per 100,000 in Caucasian population [1–4].
The increase in incidence is likely attributable, in part, to
increasing awareness, improved diagnostic strategies for NETs,
and possibly other undetermined environmental and genetic
factors [5].
NETs are a broad family of tumors with a wide range of clinical
presentations and outcomes. Given the biological diversity of
GEP-NETs, the treatment of GEP-NETs is now becoming more
optimized according to subgroups. Recently, WHO classified
NETs as well-differentiated neuroendocrine tumor, well-differen-
tiated neuroendocrine carcinoma, and poorly differentiated
neuroendocrine carcinoma [6–8]. Nevertheless, there are no
candidate biological markers to guide a novel targeted therapeutic
approach, partially owing to the fact that little is known about the
underlying mechanisms that regulate development and progres-
sion of NETs. Several clinicopathological factors have been
reported to predict poor clinical outcome in NETs. These include
histologic grade, disease stage, sex, race, age, year of diagnosis,
tumor size, and proliferation indices including Ki-67 labeling
index and mitotic count [1,9–11]. In addition to tumor size,
proliferation index are one of the most important factors
associated with metastasis. These findings suggest that certain
defects in cell cycle regulatory mechanism are associated with cell
proliferation and may predict malignant behavior of NETs. In this
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34456study, we studied gene expression signatures of cell cycle
regulatory genes in metastatic and non-metastatic colorectal NETs
to delineate candidate genes which may predict metastatic
behavior.
Materials and Methods
Patient samples
Cases of colonic (n=4) and rectal (n=15) metastatic NETs
(n=19) were selected from July 1, 1996 to December 31, 2008 who
were treated at Samsung Medical Center. This retrospective study
was approved by the institutional review board at Samsung Medical
Center and was waived for written informed consent form. Case
selection criteria for metastatic and non-metastatic NETs were as
following: complete demographic data, treatment record (Appendix
S1), availability of fresh frozen tissues and paraffin-embedded tissue
blocks. For control cases, colorectal NETs (n=22) which were
localized initially at diagnosis and during the median follow-up
period of 6.8 years (range, 3.9–10.4 years) were selected from the
database. To verify results and further investigate, another set of 38
metastatic (n=20) and non-metastatic (n=18) GEP-NETs from
pancreas (n=32), stomach (n=3), ampulla of Vater (n=1) and
rectum (n=2) were also analyzed.
A histopathologic review was conducted by two pathologists
(C.O.S and K.M.K) to verify the diagnosis and histopathology of
all cases. All study materials were obtained under the protocol
approved by the Institutional Review Board of Samsung Medical
Center. Histological grade was categorized as following; carcinoid
tumor or well differentiated NET was classified as G1 tumor,
atypical carcinoid or well differentiated neuroendocrine carcinoma
was classified as G2 tumor, and poorly differentiated neuroendo-
crine carcinoma was classified as G3 tumor [12]. Among 41 NETs
studied, 36 were G1 and 5 were G2 tumors. G3 tumors were
excluded from case selection. The demographic characteristics of
cases and controls are outlined in Table 1.
Expression of cell cycle regulatory genes by PCR Arrays
All quantitative RT-PCR experiments were conducted with a
Light Cycler 480 real-time PCR system (Roche Applied Science,
Indianapolis, IN). For PCR array experiments, a RT
2 Profiler
Custom PCR Array was used to simultaneously examine the
mRNA levels of the genes of 84 genes key to cell cycle regulation
and five reference genes including 18SrRNA, HPRT, RPL13A,
GAPDH, and b-actin, according to the protocol of the
manufacturer (SuperArray Bioscience, Frederick, MD). Total
RNAs from formalin-fixed paraffin-embedded (FFPE) tumor tissue
was extracted using RT
2 FFPE RNA extraction kit according to
the manufacturer’s instructions (SuperArray). Between 0.3 and
2.8 mg of total RNA was added to each well of the ReactionReady
First Strand cDNA Synthesis Kit (SuperArray no. C-01; Super-
Array). 5 ul of the first-strand cDNA synthesis reaction were pre-
amplified by the RT
2 PreAMP PCR Master Mix and RT
2 FFPE
PreAMP Primer Mix at 95uC for 10 min; 8 cycles of 95uC for
15 s, and 60uC for 2 min. The equivalent of 0.8 ml cDNA was
added to each well of the PCR array. A total volume of 25 mlo f
PCR mixture, which included 12.5 ml of RT2 Real-Time SYBR
Green/Fluorescein PCR master mix from SuperArray Bioscience,
11.5 ml of milliQ, and 1 ml of template cDNA, was loaded in each
well of the PCR array. Arrays were run with the following
parameters: cycle 1, 10 min at 95uC; and cycle 2, 15 sec at 95uC,
followed by 1 min at 60uC (40 repeats), with optical data collection
at 60uC for each repeat. This experiment was repeated three
times. Data were analyzed using the comparative cycle threshold
method with normalization of the raw data to 5 reference genes.
Functional gene grouping of 84 genes is shown in Table 2.
Cell cycle regulatory gene expression signature analysis
using bioinformatic methods
Volcano plot was used to identify significant differential
expression genes between metastatic NETs and non-metastatic
NETs. Briefly, the differences (log2fold change) between the two
groups wereplotted on X-axis. The –log10 (P value) wereplotted on
the y-axis. A cutoff value of P value,0.01 and fold change .1.5
were used to determine the differential gene expression signature.
Principal component analysis was performed using R program
(version 2.12.0: http://www.r-project.org) with prcomp function.
Immunohistochemistry
Immunohistochemistry (IHC) was performed for Ki-67 (clone
MIB-1, DAKO M7240, dilution 1:70) and Ataxia Telangiectasia
Mutated (ATM) (mouse monoclonal, ab78, Abcam, Cambridge,
MA, Cat No. ab78, dilution 2 ul/ml) on 3 mm sections from FFPE
tissues and mounted on positively charged slides. Tissue sections
on glass slides were deparaffinized in xylene, hydrated in
descending concentrations of alcohol, and then washed in distilled
water. Antigen retrieval was performed with a microwave for
5 minutes 2 times with 10 mM citrate buffer (pH 6.0) for Ki-67,
and with 97uC for 20 minutes with Tris/EDTA buffer (pH 8.0)
for ATM. The slides were washed in phosphate buffer for 3 times.
The slides were incubated with primary antibodies for 60 minutes,
and incubated with biotinylated antibodies (Envision plus, Dako,
Carpinteria, CA, USA) for 25 minutes and 60 minutes, respec-
tively. Endogenous peroxidase activity was blocked with 3%
hydrogen peroxide in distilled water for 10 minutes. After
washing, the slides were incubated with peroxidase-labeled
streptavidin complex for 25 minutes. The slides were incubated
in a solution of 3% diaminobenzidine for 20 minutes and
counterstained with hematoxylin. To generate Ki-67 labeling
proliferation index, image analysis was performed with the
Table 1. Characteristics of the cases used in the analysis.
Characteristic
Metastatic NET
(n=19)
non-metastatic NET
(n=22)
Age, years
Median 62 53
Range 34–79 30–72
Sex
Male 11 (41%) 16 (59%)
Female 8 (57%) 6 (43%)
Location
Rectum 15 (41%) 22 (59%)
Colon 4 (100%) 0 (0%)
Histology grade
G1 14 (39%) 22 (61%)
G2 5 (100%) 0 (0%)
Treatment
Biopsy 11 (39%) 7 (61%)
Local excision 3 (17%) 15 (83%)
Radical resection 5 (100%) 0 (0%)
NET, neuroendocrine tumor.
doi:10.1371/journal.pone.0034456.t001
ATM in Neuroendocrine Tumor
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immunostained slides were scanned under KiSight protocol for
Ki-67 analysis. A first-scan pass at 1.256objective magnification
was performed to acquire a low-resolution image to recognize the
tissue. Selection of regions of interest was performed by a
pathologist. A second scan-pass was performed at 206 objective
magnification to obtain a high resolution image. After training
color and shape classifiers, the regions were selected for analysis.
Table 2. Functional grouping of 84 cell cycle regulatory genes used in PCR array analysis.
Functional group Gene
G1 phase and G1/S transition ANAPC2, CCND1, CCNE1, CDC34, CDK4, CDK6, CDKN1B, CDKN3, CUL1, CUL2, CUL3, SKP2
S phase and DNA replication ABL1, MCM2, MCM3, MCM4, MCM5, PCNA, RPA3, SUMO1, UBE1
G2 phase and G2/M transition ANAPC2, ANAPC4, DIRAS3, BCCIP, BIRC5, CCNB1, CCNG1, CCNH, CCNT1, CCNT2, CDK5R1, CDK5RAP1,
CDK7, CDKN3, CKS1B, CKS2, DDX11, DNM2, GTF2H1, GTSE1, HERC5, KPNA2, MNAT1, SERTAD1
M phase CCNB2, CCNF, CDC2, CDC16, CDC20, MRE11A, RAD51
Cell cycle checkpoint and cell cycle arrest ATM, ATR, BRCA1, BRCA2, CCNG2, CDC2, CDC34, CDK2, CDKN1A, CDKN1B, CDKN2A, CDKN2B,
CDKN3, CHEK1, CHEK2, CUL1, CUL2, CUL3, GADD45A, HUS1, KNTC1, MAD2L1, MAD2L2, NBN,
RAD1, RAD17, RAD9A, RB1, RBBP8, TP53
Regulation of cell cycle ABL1, ANAPC2, ANAPC4, DIRAS3, ATM, ATR, BCCIP, BCL2, BRCA2, CCNB1, CCNB2, CCNC, CCND1, CCND2,
CCNE1, CCNF, CCNH, CCNT1, CCNT2, CDC16, CDC2, CDC20, CDK2, CDK4, CDK5R1, CDK6, CDK7, CDK8,
CDKN1A, CDKN1B, CKS1B, DDX11, E2F4, GADD45A, KNTC1, MKI67, PCNA, RAD9A, RB1, SKP2, TFDP1, TFDP2
Negative regulation of cell cycle ATM, BAX, BRCA1, CDKN2B, RBL1, RBL2, TP53
Bold indicate significant genes in this study.
doi:10.1371/journal.pone.0034456.t002
Figure 1. Hierarchical clustering (filtering $2 standard deviation) (A) and volcano plot (B) of expression data on cell cycle
regulatory genes. In metastatic neuroendocrine tumors, ATM, CCND2, and RBL2 were significantly down-regulated whereas CDKN3, CCNB1, and
GTSE1 were significantly up-regulated compared to non-metastatic neuroendocrine tumors (C).
doi:10.1371/journal.pone.0034456.g001
ATM in Neuroendocrine Tumor
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basis of the intensity of staining and the nuclear morphology, the
machine calculated the results as a percentage of positive cells. The
ATM positivity was defined as greater than 5% ATM (+) tumor
cells in whole tumor section area.
RNA Extraction and Real-Time Quantitative PCR of ATM
RNAs from FFPE tumor tissue was extracted using the RNeasy
FFPE Kit (QIAGEN GmbH, Hilden, Germany) according to the
manufacturer’s instructions. ATM mRNA quantification was
measured by real-time PCR based on TaqMan Gene Expression
Assays (Applied Biosystems) as previously described [13]. Glyceral-
dehyde-3-phosphate-dehydrogenase (GAPDH) mRNA was used as
an internal control to normalize ATM mRNA level. Real-time PCR
quantitation of transcripts was expressed as ATM/GAPDH ratios.
Statistical analysis
Differences between metastatic NET and non-metastatic NET
samples were calculated using t-test or Mann-Whitney U test as
appropriate. Correlations were examined Pearson’s x
2, Fisher’s
exact test, Pearson’s or Spearman’s test as appropriate. Overall
survival (OS) was determined using the Kaplan-Meier method and
survival curves were compared using the long-rank test. Survival
was calculated from the date of diagnosis and all patients were
followed through March 23, 2011. All tests were two-sided and
statistical significance was set at a threshold of p,0.05. Statistical
analyses were performed using R program or SPSS (SPSS 18,
Chicago, IL, USA).
Results
Metastatic NETs show different expression patterns of
cell cycle regulatory genes
Of 19 metastatic NETs, 13 samples passed the initial quality
control for RNA and 18 of 22 non-metastatic NETs passed the
quality check and thus included for cell cycle regulatory gene
expression profile analysis. The experiment was repeated three
times with the same result. Hierarchical clustering analysis of
gene expression data (filtering $2s t a n d a r dd e v i a t i o n )f r o ma l l
tissues revealed that metastatic NETs and non-metastatic NETs
were clustered with distinctive separation at the end of both sides
with few exceptions (Figure 1A). Thus, gene expression pattern of
cell cycle regulatory genes in metastatic NETs was apparently
distinct from that observed in non-metastatic NETs. Next step, to
identify significantly different set of genes expressed between the
two groups, we applied volcano plot considering both p value (by
two-sample t test) and fold-changes (metastatic vs non-metastatic
NETs). Using this method, we selected six genes including ATM,
CCND2, RBL2, CDKN3, CCNB1,a n dGTSE1 which are
significantly associated with metastasis (Figure 1B). Among them,
ATM, CCND2,a n dRBL2 were significantly down-regulated in
metastatic NETs, whereas CDKN3, CCNB1,a n dGTSE1 were
significantly up-regulated in metastatic NETs (all six genes,
p,0.05, Figure 1C). Of note, ATM showed the lowest p value
(p,0.001) with more than 2-fold change between non-metastatic
vs metastatic NETs.
Figure 2. Correlation analysis of six genes reveals relationship with each other. Expression of ATM was only significantly associated with all
other 5 genes (A). Principal component analysis showed separation of metastatic and non-metastatic neuroendocrine tumors with contributing
genes (B). Network interaction diagram constructed based on correlation of six genes (C).
doi:10.1371/journal.pone.0034456.g002
ATM in Neuroendocrine Tumor
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ATM plays key role as a tumor suppressor in NETs
In the correlation analysis of six genes, only ATM expression was
consistently correlated with expressions of all other 5 candidate genes
with statistical significance (Figure 2A). ATM expression demonstrat-
ed strong positive correlations with CCND2 and RBL2,a n dn e g a t i v e
correlations with CDKN3, CCNB1,a n dGTSE1. Using these six genes,
principal component analysis was performed which revealed two
distinct groups of metastatic and non-metastatic NETs (Figure 2B).
Furthermore, principal component analysis suggested that CCNB1,
CDKN3,a n dGTSE1 were important genes associated with metastatic
NETs, whereas ATM and RBL2 were highly expressed in non-
metastatic NET with CCND2 expressed in minor group of non-
metastatic NETS. ATM and RBL2 are already known as negative
regulators of cell cycle which support their role as tumor suppressor
genes [14,15]. In line with these findings, a network interaction
diagram constructed based on correlation analyses clearly showed
that an ATM down-regulation leads to increased expressions of
CDKN3, CCNB1,a n dGTSE1 ( F i g u r e2 C ) .B a s e do nt h e s er e s u l t s ,
ATM seems to be one of the key regulators for cell cycle in NETs.
ATM gene down-regulation is strongly associated with
metastatic NET and proliferation of tumor cells
To validate ATM protein expression, we performed ATM IHC
from 14 of 19 metastatic NETs, and 17 of 22 non-metastatic NETs
due to availability of FFPE tissue specimens. ATM IHC revealed
nuclear staining of tumor cells (Figure 3A), and 15 (48.4%) of 31
cases were positive for ATM staining. The ATM positivity was
defined as greater than 30% ATM (+) tumor cells in whole tumor
areas. Moreover, ATM overexpression was strongly correlated
with high ATM mRNA levels (Figure 3B) and low Ki-67 labeling
index (Figure 3B). In line with these results, we identified that Ki-
67 labeling index and mean mitotic counts were considerably
increased in metastatic NETs (Figure 3C). Of 14 metastatic NETs,
12 cases (85.7%) were ATM-negative, which indicated that ATM
down-regulation is strongly associated with metastatic NETs.
However, there was no significant relationship between ATM
expression and various clinicopathologic parameters including
tumor site, grade, gender and age (Table 3). Accordingly, patients
with ATM-negativity showed significantly decreased overall
survival than patients with ATM-positivity (p=0.003, Figure 3D),
which correlated well with their metastatic behaviors.
ATM RNA expression levels in validation set
In the validation set of 20 metastatic and 18 non-metastatic
GEP-NETs from various organs including pancreas, stomach,
ampulla of Vater and rectum, mean mRNA levels of ATM in
metastatic NETs were significantly low in metastatic NETs
compared to non-metastatic NETs (p=0.023) (Figure 4).
Figure 3. ATM immunohistochemistry in colorectal neuroendocrine tumors. ATM protein expression was significantly correlated with high
ATM mRNA expression and low Ki-67 labeling index (A, B). Ki-67 labeling index and mean mitotic counts were increased in metastatic neuroendocrine
tumors (C). Patients with negative ATM protein expression showed significantly shorter overall survival than patients with positive ATM protein
expression (D).
doi:10.1371/journal.pone.0034456.g003
ATM in Neuroendocrine Tumor
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We investigated differential gene expression signatures of
metastatic vs non-metastatic colorectal NETs focusing on cell
cycle regulatory gene set, and delineated six candidate genes for
metastasis including ATM, CCND2, RBL2, CDKN3, CCNB1, and
GTSE1. Among them, we have focused on ATM since ATM has
been known as a tumor suppressor gene which encodes a principal
DNA damage-signaling protein. In this study, decreased expres-
sion of ATM protein was strongly correlated with low ATM
mRNA levels and high Ki-67 labeling index. Tumor cells with
ATM dysfunction exhibit increased loss of cell cycle check points
and p53 dysfunction in selected cancer types [16–18]. For the first
time, we demonstrated here that ATM down-regulation was
strongly associated with metastatic NETs when compared with
non-metastatic NETs and that .80% of metastatic NETs do not
express ATM protein.
In our study, low ATM mRNA expression was significantly
associated with increased expression of CDKN3, GTSE1, and
CCNB1 as well as high Ki-67 proliferation index. These findings
suggest that ATM down-regulation can lead to increased cell cycle
regulatory genes such as CDKN3 and CCNB1, and then increased
CDKN3 and CCNB1 leading to increased cell division and cell
proliferation. CDKN3, also known as kinase-associated phospha-
tase (KAP), is another molecule involved in cell cycle checkpoint
and cell cycle arrest. It has been reported that KAP is over-
expressed in breast and prostate tumors, and is associated with
proliferation of tumor cells [19]. We also found that RBL2, a key
regulator of entry into cell division was significantly down-
regulated in metastatic neuroendocrine tumors, suggesting
growth-suppressive properties of RBL2 was decreased and tumor
cells proloferate [20].
ATM gene has been described to be causal gene of Ataxia-
telangiectasia, and inactivation of ATM is associated with
increased risk of carcinogenesis and radiosensitivity [21–24].
Bartkova et al. [25] suggested that tumorigenic events early in
the progression of major human cancer types activate the ATM-
regulated checkpoint through deregulated DNA replication and
DNA damage, and thereby activate an inducible barrier against
tumor progression and genetic instability. Loss-of-function events
in the ATM-Chk2-p53 tumor-suppressive cascade facilitates
survival and proliferation of genetically unstable cancer cells
[26]. Main mechanism of ATM inactivation in ataxia-telangiec-
tasia associated patient is mutation such as truncating mutation
and missense mutation, and missense mutation might be more
prone to carcinogenesis [27]. Mutational inactivation of the ATM
gene has been demonstrated in mantle cell lymphoma, T-cell
prolymphocytic leukemias, rhabdomyosarcomas, and gastric
cancer [28–31], and ATM heterozygous state is more common
in breast cancer patients than in the general population [32,33].
On the other hand, promoter methylation or deletion of ATM
seems to be important mechanism for ATM inactivation in some
sporadic cancers. Indra et al. [34] reported that 36% of cervical
cancer samples showed ATM promoter methylation and 31% of
cervical cancer samples showed ATM deletion. However, mutation
in ATM gene was rare [35]. Ai et al. [36] also reported that
frequent aberrant methylation of ATM promoter (25% of 100
samples) was found in head and neck squamous cell carcinomas.
Both two mechanisms including methylation and deletion were
well correlated with reduced mRNA and protein expression of
ATM [34,37]. Methylation or deletion of ATM may be a
mechanism for reduced expression in NET, however, in our
study, because of further study need to confirm.
Cell lines derived from Ataxia-telangiectasia patients exhibit
abnormalities related to DNA damage and repair such as
chromosomal instability, cell-cycle checkpoint defects in G1/S
and G2/M, sensitivity to ionizing radiation and telomere end-to-
end fusions [38]. There is a growing evidence that oral poly (ADP-
ribose) polymerase inhibitor, olaparib impedes the growth of ATM
null or ATM mutant lymphoma cells in vitro and in vivo by
Table 3. Relationships between ATM protein expression and
various clinicopathologic factors in colorectal neuroendocrine
tumors.
ATM expression
Characteristics n Negative Positive P value
Tumor site
Colon 4 4 0 0.101
Rectum 27 12 15
Grade
G1 27 12 15 0.101
G2 4 4 0
Sex
Female 8 6 2 0.22
Male 23 10 13
Age
,60 18 9 9 0.833
$60 13 7 6
Tumor behavior
Metastatic tumor 14 12 2 0.001
Non-metastatic tumor 17 4 13
doi:10.1371/journal.pone.0034456.t003
Figure 4. Comparison of mRNA expression levels of ATM in
metastatic (mean=0.5370±0.33263, median=0.3912, mini-
mum 0.14, maximum 1.13) and non-metastatic GEP-NETs
(mean=1.5075±1.22467, median=0.7964, minimum 0.44,
maximum 3.80).
doi:10.1371/journal.pone.0034456.g004
ATM in Neuroendocrine Tumor
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in cycling tumor cells [39,40]. Consistent with these reports, ATM
knockdown breast cancer cells, like BRCA1/2 null cells, exhibited
selective sensitivity to PARP inhibition. Given the recent positive
results from phase III trial comparing conventional chemotherapy
to chemotherapy plus olaparib or iniparib in breast cancer,
[39,40]. Currently, there is no standard treatment for metastatic
NETs although recent trials support the use of everolimus or
sunitinib as one of the treatment options [41]. In contrast to the
NETs in the West, where pancreatic NET is the most prevalent
NETs, colorectum is the most common anatomic tumor location
in Asia [1,42]. Hence, a clinical research with PARP inhibitor in
ATM-negative colorectal NETs should be actively implemented in
Asian countries.
One of the major limitations of this study was small number of
tumor specimens owing to the rarity of metastatic NETs with
limited availability of fresh frozen tissues for gene expression
profiling. Distant metastases in rectal NETs are associated with 1.7
to 8.1% [43], and approximately 16 to 40% of colonic NETs [44].
The median survival of metastatic colorectal NETs ranges from 6
to 18 months. We showed that ATM-negativity was not
significantly correlated with clinicopathologic parameters such as
tumor site, histology grade, sex, and age. However, there was a
tendency towards ATM negativity in colon NETs and G2 NETs
when compared with rectal NETs and G1 NETS, respectively,
although statistical significance was not reached (p.0.05).
In conclusion, our study identified six significant cell cycle
regulating genes associated with metastatic colorectal NETs, and
down-regulation of ATM and ATM-mediated cell cycle signaling is
indicated as a key regulatory molecule leading to increased cell
proliferation and involves metastasis in colorectal NETs. The anti-
tumor effect of PARP inhibitor in ATM-negative, metastatic
NETs should be studied in the context of clinical trials. Further
studies are warranted to explain underlying biological and
molecular mechanisms and develop new therapeutic targets.
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